Plain-English translation of NCT04416581 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Coronary Artery Disease research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether tegoprazan, a newer acid-blocking medication, works as well as or better than rabeprazole (a standard acid blocker) at protecting the stomach in people with heart disease who must take blood-thinning medications. Blood thinners save lives by preventing clots, but they can increase the risk of stomach bleeding. This study will see if the newer medication provides better protection.
Many people with heart disease need to take blood thinners long-term, but these medications carry a risk of serious stomach bleeding. Doctors already use acid-blocking medications to reduce this risk, but researchers want to know if this newer treatment might offer better or safer protection.
You likely qualify if…
You likely don't qualify if…
First, the study will enroll 300 people in a safety phase to make sure the newer medication is safe. If no safety concerns arise, the main trial will enroll 3,100 participants who will be randomly assigned to take either the newer medication or the standard one, once daily, for several months. You will take a pill each day and have periodic check-ups to monitor your stomach health and safety.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
South Korea